NCT06514534 2026-04-21
ASC4TARGET
Novartis
Phase 2 Recruiting
Clinical Trials
7 trialsNCT06368414 2026-04-02
AsterA
Korean Society of Hematology
Phase 2 Recruiting
NCT05143840 2026-03-23
ALERTCML
Augusta University
Phase 2 Recruiting
NCT06236724 2026-03-04
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06629584 2026-02-17
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT06409936 2025-07-08
PEARL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting